Vanguard Global Advisers
ORKA

Vanguard Global Advisers’s Oruka Therapeutics ORKA Stock Holding History

Vanguard Global Advisers’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.36M Buy
24,783
+3,413
+16% +$227K ﹤0.01% 1149
2026
Q1 		$1.05M Buy
+21,370
New +$743K ﹤0.01% 1629

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Global Advisers's ORKA Position: Q2 2026 in Review

Vanguard Global Advisers increased its Oruka Therapeutics (ORKA) stake by 16% in Q2 2026, buying an estimated $227K and bringing the position to 24,783 shares worth $2.36M. The position accounts for ﹤0.01% of the portfolio, ranked #1149.

Vanguard Global Advisers first reported a position in ORKA in Q1 2026 and has held it in 2 quarters since. 254 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Vanguard Global Advisers held 24,783 shares of Oruka Therapeutics worth $2.36M as of Q2 2026.
  • Vanguard Global Advisers bought 3,413 Oruka Therapeutics shares in Q2 2026, an estimated $227K.
  • Oruka Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1149 holding.
  • Vanguard Global Advisers first reported a position in Oruka Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 254 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.